VERISILICON
9.4.2024 09:01:28 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced its demonstration at Embedded World 2024 in Nuremberg, Germany, booth numbered Hall 4A-518, where it is showcasing customers’ various leading products leveraging the company’s latest technologies and advanced solutions.
VeriSilicon’s one-stop custom silicon services and semiconductor IP licensing services provide customers with intelligent, secure, and highly adaptable solutions, addressing a wide range of key areas such as Artificial Intelligence (AI) and Machine Learning, Internet of Things (IoT), Consumer Electronics and Smart Devices, Data Center and High-Performance Computing, Smart Healthcare, and Automotive Electronics. Highlighted demonstrations include:
- AI and Machine Learning: A high-performance AI-PC with Blue Ocean’s chiplet acceleration card using GPGPU and NPU IPs powered by VeriSilicon, Google Open Se Cura powered by VeriSilicon, Inuitive vision AI processor featuring VeriSilicon’s dual-channel Image Signal Processor (ISP) IP.
- IoT: VeriSilicon’s LE Audio compliant complete Bluetooth Low Energy IP solution, LE Mesh system solution based on VeriSilicon’s BLE technology.
- Consumer Electronics and Smart Devices: A next-generation 8K TV and a leading Smart Camera integrated with VeriSilicon’s Neural Network Processor (NPU) IP, a next-generation Drone featuring VeriSilicon’s Video Processor Unit (VPU) IP, Smart Watches and Smart AR Glasses based on VeriSilicon’s Graphics Processor Unit (GPU) IP and Display Processor IP, Smart Home devices embedded with VeriSilicon’s IPs.
- Data Center and High-Performance Computing: VeriSilicon’s second-generation data center video transcoding platform solution.
- Smart Healthcare: VeriHealthi health monitoring platform based on VeriSilicon’s ZSP Digital Signal Processor (DSP) and BLE IPs.
- Automotive Electronics: Automotive SoC enabled by VeriSilicon’s ISO 26262 compliant IPs and subsystems.
VeriSilicon’s semiconductor IP licensing business holds the largest market share in China and ranks seventh worldwide1. Among the top ten IP companies globally, VeriSilicon’s number of IP categories ranks top two2. With over two decades of expertise in the GPU sector, VeriSilicon’s GPU IP has been shipped in nearly two billion chips. Additionally, VeriSilicon’s self-developed NPU IP has been integrated into 128 AI SoCs supplied by 72 licensees in more than 10 market segments, and has been shipped in over 100 million AI-enabled chips worldwide. In terms of video processing, VeriSilicon’s first-generation video transcoding acceleration solution, which is integrated with the company’s VPU IP, provides 6 times the transcoding capability of traditional high-end CPUs while consuming only 1/13 of the power. This innovative technology has been successfully applied to media accelerator chips custom-made for leading global chip companies based on the 5nm process and has entered the mass production stage.
As part of the Embedded World conference program, VeriSilicon’s Vice President of Vision Image Product Shang-Hung Lin will deliver a keynote speech themed Implementing Transformer Neural Networks for Visual Perception on Embedded Devices during Session 7.8 on Embedded Vision & Edge AI, scheduled for April 10 at 1:45pm.
“We are thrilled to present our latest and innovative IP solutions at Embedded World 2024. Our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio is silicon-proven, production-proven, and application-proven, which is configurable for a wide range of applications, ranging from low-power-focused to high-performance data center uses,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “In addition to our own IP offerings, we have also collaborated with third-party partners such as RISC-V IP providers and GUI software providers to deliver competitive solutions to our customers. Our commitment to IP innovations is aimed at empowering our customers’ success, enabling them to introduce innovative products to the market more quickly.”
To experience live demos and engage with VeriSilicon’s experts, please visit our booth at Messezentrum Nürnberg (Booth No.: Hall 4A-518) or schedule a meeting with us via email at eu-sales@verisilicon.com.
1 According to IPnest, April 2023
2 According to IPnest’s IP categorization and companies’ disclosure information
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409713011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom